Celltrion Gets FDA Nod For Subcutaneous Infliximab
Zymfentra, Marketed Globally As Remsima SC, Receives Approval In US
Celltrion has received FDA approval for Zymfentra, its subcutaneous formulation of infliximab that is marketed in other global territories as Remsima SC.
